CancerICD-10: C91-C95About 60,000 new cases diagnosed annually in the U.S.

Leukemia

Also known as: Blood Cancer, Cancer of the Blood

Leukemia is a group of cancers that begin in blood-forming cells of the bone marrow, leading to overproduction of abnormal white blood cells. It is classified by speed (acute vs. chronic) and cell type (lymphocytic vs. myeloid). Advances in chemotherapy, targeted therapy, and stem cell transplantation have dramatically improved survival rates.

Last updated November 10, 2026

Understanding Leukemia

Leukemia is a cancer of the blood-forming cells of the bone marrow. A single stem or progenitor cell acquires mutations that let it multiply without maturing properly, and its descendants crowd the marrow and spill into the blood. It is not one disease but four main ones, split by speed and cell type: acute lymphoblastic leukemia (ALL), the commonest cancer of children, peaking between ages 2 and 5; acute myeloid leukemia (AML), mostly a disease of adults over 65; chronic lymphocytic leukemia (CLL), the commonest adult leukemia in Western countries with a median age at diagnosis around 70; and chronic myeloid leukemia (CML). The American Cancer Society expects about 67,000 new cases and 23,500 deaths in the United States in 2025. Survival now differs enormously by type: more than 90 percent of children with ALL are alive at five years, people with CML on modern tablets have a near-normal life expectancy, CLL five-year survival is about 88 percent, and AML remains the hardest, with five-year survival around 30 percent overall and well under that after 65.

Healthy marrow produces about 200 billion red cells and 100 billion white cells a day under tight control. In leukemia, mutations in genes such as FLT3, NPM1 and IDH1 or IDH2 in AML, or the BCR-ABL fusion created by the Philadelphia chromosome in CML and some ALL, lock cells into dividing. In acute leukemia the marrow fills with immature blasts within weeks, so the symptoms are those of missing normal cells: anemia causing fatigue and breathlessness, low neutrophils causing fevers and infections, and low platelets causing bruising, nosebleeds and the pinpoint petechiae of the shins. Untreated, acute leukemia is fatal within weeks to months. Chronic leukemias produce cells that mature almost normally and accumulate over years; many people with CLL are found on a routine blood count, feel well, and are watched for years before any treatment is needed. A precursor state called clonal hematopoiesis is now known to be common after 70 and progresses to a blood cancer at only about 0.5 to 1 percent a year, which is one reason a mildly abnormal count rarely means leukemia.

Treatment is type-specific and guided by the NCCN and, for AML, the European LeukemiaNet 2022 recommendations. CML is the model success: imatinib produced 83 percent 10-year survival in the IRIS trial, and about half of people who hold a deep molecular remission for two years can stop the drug under monitoring and stay in remission. CLL has moved almost entirely from chemotherapy to targeted agents: BTK inhibitors such as acalabrutinib and zanubrutinib, or a fixed one-year course of venetoclax plus obinutuzumab, which in the 432-patient CLL14 trial kept 63 percent of patients progression-free at five years. AML still relies on intensive '7+3' chemotherapy in fit patients, with FLT3 inhibitors added for FLT3-mutated disease and an allogeneic stem cell transplant for high-risk genetics; for older or frailer patients, venetoclax plus azacitidine extended median survival from 9.6 to 14.7 months in the VIALE-A trial. Childhood ALL is treated with two to three years of multi-agent chemotherapy, and for relapse the immunotherapies blinatumomab and the CAR-T product tisagenlecleucel have changed the outlook. Supportive care, meaning transfusions, antibiotics and antifungals, prevents most treatment deaths.

No supplement, herb or diet treats leukemia, and because treatment depends on precise drug levels and a fragile immune system, the question is less what helps than what interferes. Tyrosine kinase inhibitors such as imatinib, dasatinib and ibrutinib, and venetoclax, are broken down by the liver enzyme CYP3A4: St John's wort lowers imatinib exposure by about 30 percent, while grapefruit, Seville orange and high-dose curcumin or quercetin can push levels up. Green tea extract has a genuine but small signal in early CLL, where a 42-patient Mayo Clinic trial found a high-dose extract shrank lymphocyte counts or nodes in two-thirds, but it has never been shown to delay treatment or extend life, and at those doses it has caused liver injury. Probiotic supplements have caused bloodstream infections in neutropenic patients and should be avoided during intensive treatment.What does help, modestly, is ginger for chemotherapy nausea, correcting a low vitamin D, which is common in CLL and associated with faster progression in observational studies, and oral glutamine for some patients with mouth sores. Everything else marketed for 'blood cancer' lacks trials.

The most common mistake is underestimating a fever. During chemotherapy, and for weeks after, the neutrophil count can fall near zero, and a bacterial infection can progress to sepsis in hours without any of the usual signs. A temperature of 100.4 F (38 C) or higher is an emergency in anyone with a low neutrophil count: call the oncology line or go to the emergency department, do not take acetaminophen and wait to see, and expect intravenous antibiotics within an hour of arrival, which is the standard in ASCO and IDSA guidance. The second mistake is stopping or stretching targeted tablets because of cost or side effects without telling the team: in CML, taking less than 90 percent of imatinib doses was associated with a fall in major molecular response from 94 to 28 percent, and most side effects can be managed with a dose change or a switch. The third is assuming CLL on watch-and-wait is being neglected; starting treatment early in asymptomatic disease has never improved survival in randomized trials, and waiting is the evidence-based choice.

At a Glance

Common symptoms
Persistent fatigue and weakness, Frequent infections or fevers, Easy bruising and excessive bleeding
Main treatments
Chemotherapy (induction, consolidation, maintenance phases), Targeted therapy (imatinib for CML, FLT3 inhibitors for AML), Immunotherapy and CAR-T cell therapy
Category
Cancer · About 60,000 new cases diagnosed annually in the U.S.
See a doctor if
Persistent unexplained fatigue, fever, or infections

Symptoms

Persistent fatigue and weakness
Frequent infections or fevers
Easy bruising and excessive bleeding
Petechiae (tiny red dots on the skin)
Unexplained weight loss and night sweats
Bone or joint pain
Swollen lymph nodes, liver, or spleen
Shortness of breath

Causes

  • Genetic mutations in bone marrow stem cells
  • Chromosomal abnormalities (Philadelphia chromosome in CML)
  • Previous chemotherapy or radiation exposure
  • Certain genetic syndromes (Down syndrome, Fanconi anemia)
  • Exposure to high levels of radiation or benzene

Risk Factors

  • Previous cancer treatment with certain chemo drugs or radiation
  • Genetic disorders (Down syndrome, Li-Fraumeni syndrome)
  • Exposure to benzene or radiation
  • Smoking (increases risk of AML)
  • Family history of leukemia

Diagnosis

  • CBC showing abnormal white blood cell counts
  • Peripheral blood smear showing blast cells
  • Bone marrow biopsy and aspiration
  • Flow cytometry and cytogenetic analysis
  • Molecular testing for specific mutations

Treatment

  • Chemotherapy (induction, consolidation, maintenance phases)
  • Targeted therapy (imatinib for CML, FLT3 inhibitors for AML)
  • Immunotherapy and CAR-T cell therapy
  • Allogeneic stem cell transplant for high-risk patients
  • Radiation therapy in specific situations
  • Supportive care (transfusions, antibiotics, growth factors)

Natural remedies for leukemia: what the evidence says

Ranked by the strength of human evidence for leukemia specifically. These sit alongside medical care, not in place of it.

  1. Ginger

    Moderate evidence

    In a 576-patient randomized trial across cancer types, 0.5 to 1 g of ginger extract daily for six days around each chemotherapy cycle, alongside standard antiemetics, reduced acute nausea compared with placebo. Meta-analyses since have been mixed, with more consistent benefit for nausea than for vomiting, so it is an add-on to the prescribed antiemetics rather than a replacement. It has no effect on the leukemia itself.

    Studied dose
    0.5 to 1 g of standardized ginger extract daily in two divided doses, starting 3 days before chemotherapy and continuing for 3 days after, with prescribed antiemetics.
    Cautions
    Ginger has a mild antiplatelet effect, which matters when platelets are low from the disease or from chemotherapy, and it adds to anticoagulants; it can worsen reflux. Stop it a week before any procedure, and clear it with the hematology team first.
  2. In 390 newly diagnosed CLL patients at the Mayo Clinic, 30 percent were vitamin D insufficient, and those patients had a shorter time to first treatment and shorter overall survival, a finding repeated in a second cohort of 153. That is an association, not proof that supplements change the course, and no randomized trial has tested vitamin D as a treatment in any leukemia. Correcting a documented low level is sensible anyway, because steroids used in ALL and CLL regimens and months indoors during treatment both weaken bone.

    Studied dose
    If 25-hydroxyvitamin D is below 20 ng/mL (50 nmol/L), 1,000 to 2,000 IU vitamin D3 daily, rechecked after 3 months; there is no evidence for higher doses in leukemia.
    Cautions
    Doses above 4,000 IU daily without monitoring can raise calcium, which is already a risk in some blood cancers. Ask for a vitamin D level rather than guessing, and tell the team you are taking it so it can be accounted for in bone-health decisions.
  3. Green tea extract (EGCG)

    Preliminary evidence

    EGCG kills CLL cells in the laboratory, and in a Mayo Clinic phase 2 trial, 42 people with early-stage CLL who did not yet need treatment took a standardized extract (Polyphenon E, 2,000 mg twice daily) for 6 months; 69 percent had at least a 20 percent fall in lymphocyte count or a 50 percent reduction in lymph node size. No trial has shown it delays the need for treatment or lengthens life, it has no evidence in AML, ALL or CML, and it is not a substitute for monitoring by a hematologist.

    Studied dose
    2,000 mg of a standardized green tea extract (roughly half EGCG) twice daily with food, as studied for 6 months in early CLL; ordinary green tea provides far less.
    Cautions
    Concentrated extracts at 800 mg EGCG a day or more have caused liver injury, and transaminases rose in the trial, so liver enzymes need monitoring. EGCG can reduce the effect of bortezomib, may alter levels of drugs handled by CYP3A4, and reduces iron and folate absorption; take it only with your hematologist's agreement.
  4. L-Glutamine (for mouth sores)

    Preliminary evidence

    Chemotherapy mucositis is common in acute leukemia regimens. In a 326-patient trial in breast cancer, an oral glutamine suspension reduced moderate-to-severe mouth sores from 50 to 39 percent, and a crossover study in 24 children on chemotherapy found that swish-and-swallow glutamine shortened the duration of mouth pain by about 4 days. Results across trials are inconsistent, the MASCC/ISOO 2020 guideline could not recommend it for chemotherapy mucositis, and it recommends against the intravenous form in stem cell transplant patients.

    Studied dose
    10 g of L-glutamine powder dissolved in water, swished and swallowed two to three times a day, starting with each chemotherapy cycle and continuing until the mouth has healed.
    Cautions
    Avoid in liver failure and take advice if you have seizures or kidney disease. Do not use intravenous glutamine in stem cell transplant, where a trial raised concern about relapse. Oral glutamine can cause bloating and does not replace the oral care protocol your unit provides.

What matters day to day

  • Treat a temperature of 100.4 F (38 C) or higher as an emergency whenever your neutrophils could be low: call the oncology line or go to the emergency department, because infection without white cells can become sepsis in hours, and guidelines expect antibiotics within an hour of arrival.
  • Follow neutropenic food safety when counts are low: wash hands and surfaces, cook meat and eggs through, avoid raw sprouts, unpasteurized dairy and juices, and soft cheeses, since the usual bacteria in food become dangerous without neutrophils to clear them.
  • Get inactivated vaccines (influenza, COVID-19, pneumococcal) when your team advises and avoid live vaccines such as MMR, varicella and nasal-spray flu during treatment and for months after: inactivated vaccines are safe but work best when given before chemotherapy or between cycles, and household contacts should be vaccinated to protect you.
  • Keep moving, even during inpatient chemotherapy: in pooled trials of people with blood cancers, supervised exercise reduced fatigue and preserved fitness during treatment, and a daily walk around the ward plus light resistance work is realistic for most patients.
  • If you have CLL, use sun protection every day and have a dermatologist check your skin at least once a year: skin cancer is several times more common in CLL than in the general population and behaves more aggressively, because the disease and its treatments weaken immune surveillance of the skin.
  • Avoid aspirin, ibuprofen and naproxen unless prescribed, use a soft toothbrush, and have a dental review before chemotherapy starts: all three protect against bleeding and infection when platelets and neutrophils are low, and dental infections are a common source of sepsis during treatment.

When to See a Doctor

  • Persistent unexplained fatigue, fever, or infections
  • Unusual bruising, bleeding, or petechiae
  • Swollen lymph nodes, bone pain, or unexplained weight loss
  • Blood tests show abnormal cell counts

Frequently Asked Questions

References

  1. Hochhaus A, Larson RA, Guilhot F, et al.. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. New England Journal of Medicine (2017)
  2. DiNardo CD, Jonas BA, Pullarkat V, et al.. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. New England Journal of Medicine (2020)
  3. Fischer K, Al-Sawaf O, Bahlo J, et al.. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. New England Journal of Medicine (2019)
  4. Maude SL, Laetsch TW, Buechner J, et al.. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine (2018)
  5. Dohner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood (2022)
  6. Shanafelt TD, Call TG, Zent CS, et al.. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer (2013)
  7. Shanafelt TD, Drake MT, Maurer MJ, et al.. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2011)
  8. Frye RF, Fitzgerald SM, Lagattuta TF, et al.. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clinical Pharmacology and Therapeutics (2004)
  9. Taplitz RA, Kennedy EB, Bow EJ, et al.. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. Journal of Clinical Oncology (2018)
  10. National Cancer Institute. Leukemia (2025)View source

Related Conditions

Have questions about Leukemia?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.